1. Home
  2. EQ vs EVAX Comparison

EQ vs EVAX Comparison

Compare EQ & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • EVAX
  • Stock Information
  • Founded
  • EQ 2017
  • EVAX 2008
  • Country
  • EQ United States
  • EVAX Denmark
  • Employees
  • EQ N/A
  • EVAX N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EQ Health Care
  • EVAX Health Care
  • Exchange
  • EQ Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • EQ 13.1M
  • EVAX 15.1M
  • IPO Year
  • EQ 2018
  • EVAX 2021
  • Fundamental
  • Price
  • EQ $0.93
  • EVAX $2.85
  • Analyst Decision
  • EQ Buy
  • EVAX Strong Buy
  • Analyst Count
  • EQ 3
  • EVAX 2
  • Target Price
  • EQ $3.00
  • EVAX $10.00
  • AVG Volume (30 Days)
  • EQ 21.2M
  • EVAX 106.2K
  • Earning Date
  • EQ 08-19-2025
  • EVAX 08-14-2025
  • Dividend Yield
  • EQ N/A
  • EVAX N/A
  • EPS Growth
  • EQ N/A
  • EVAX N/A
  • EPS
  • EQ N/A
  • EVAX N/A
  • Revenue
  • EQ $30,406,000.00
  • EVAX $3,293,000.00
  • Revenue This Year
  • EQ N/A
  • EVAX N/A
  • Revenue Next Year
  • EQ N/A
  • EVAX N/A
  • P/E Ratio
  • EQ N/A
  • EVAX N/A
  • Revenue Growth
  • EQ N/A
  • EVAX 2555.64
  • 52 Week Low
  • EQ $0.27
  • EVAX $1.20
  • 52 Week High
  • EQ $1.50
  • EVAX $17.75
  • Technical
  • Relative Strength Index (RSI)
  • EQ 71.79
  • EVAX 56.89
  • Support Level
  • EQ $0.46
  • EVAX $2.61
  • Resistance Level
  • EQ $1.25
  • EVAX $2.99
  • Average True Range (ATR)
  • EQ 0.20
  • EVAX 0.20
  • MACD
  • EQ 0.04
  • EVAX -0.00
  • Stochastic Oscillator
  • EQ 57.41
  • EVAX 62.50

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

About EVAX Evaxion Biotech

Evaxion AS is in the field of oncology. It used the AI-Immunology platform.

Share on Social Networks: